The treatment of idiopathic sudden sensorineural hearing loss (SSNHL) continues to be a substantial clinical challenge, in part because of the heterogeneity of the patient population and in part because of the difficulty of studying a disorder with no known causes and no defined, proven, or widely accepted course of clinical intervention. We read with interest the systematic review and meta-analysis by Joshua and colleagues1 on hyperbaric oxygen therapy (HBOT) for patients with SSNHL. Rhee and colleagues published a review of the same topic in 20192; however, their conclusions were criticized for significant heterogeneity of the pooled studies, which introduced potentially unsurmountable bias.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Moody-Antonio SA, Chandrasekhar SS, Derebery MJ. Is It Time to Encourage Hyperbaric Oxygen Therapy in Combination With Medical Treatment for Sudden Sensorineural Hearing Loss? JAMA Otolaryngol Head Neck Surg. Published online October 28, 2021. doi:10.1001/jamaoto.2021.2957
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.